+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF and plasma somatostatin levels in acromegaly



CSF and plasma somatostatin levels in acromegaly



Clinical Endocrinology 13(3): 235-241



Cerebrospinal fluid (CSF) and plasma levels of somatostatin have been measured in patients with active acromegaly and the results compared to those obtained in patients with non-endocrine diseases. Plasma levels have also been studied in acromegalics given oral glucose. The mean CSF somatostatin level in twenty patients without endocrine disease was 76 pg/ml (range 46-112) which did not differ significantly from that found in eight acromegalics (mean 87 pg/ml, range 48-160). Plasma somatostatin in twenty-two acromegalic patients on no medical treatment was 43 pg/ml (range 9-113), not significantly different from values in a normal control population. There were no differences in the somatostatin levels of non-diabetic acromegalics. After oral glucose, there was a rise in circulating somatostatin in eleven out of twelve acromegalic patients, and this rise did not differ from that seen in normal subjects. It is probable that altered somatostatin secretion is neither the cause nor the result of acromegaly; however it is possible that local changes in somatostatin concentration which are not reflected in peripheral plasma or CSF levels may occur near the site of its production.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 042429237

Download citation: RISBibTeXText

PMID: 6111404

DOI: 10.1111/j.1365-2265.1980.tb01048.x


Related references

Cerebro spinal and plasma somatostatin levels in acromegaly. Clinical Endocrinology 13(3): 235-242, 1980

Insulin-like factor 3 plasma levels in acromegaly before and after somatostatin analog treatment. Endocrine 48(2): 705-708, 2015

Effects of somatostatin of plasma levels of glucose, insulin and growth hormone in acromegaly. Minerva Medica 67(50): 3241-3242, 1976

Effect of octapeptide somatostatin analogue (SMS 201-995) on plasma 7B2 (a neuroendocrine polypeptide) levels in patients with acromegaly. Clinical Endocrinology 32(1): 49-55, 1990

A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly. Clinical Endocrinology 5(2): 167-174, 1976

Plasma levels of somatostatin following a test meal in dogs. Initial atropine resistant vagally mediated decrease of somatostatin levels and increase of gastrin and insulin levels. Acta Physiologica Scandinavica 114(2): 253-259, 1982

Initial fall in peripheral plasma somatostatin-like immunoreactivity levels following feeding in humans indicating a vagal inhibitory control of somatostatin levels. Acta Physiologica Scandinavica 113(3): 411-413, 1981

Elevated circulating somatostatin levels in acromegaly. Journal of Endocrinological Investigation 26(6): 499-502, 2003

Disappearance of plasma growth hormone in acromegaly and protein-calorie malnutrition after somatostatin. Journal of Clinical Endocrinology and Metabolism 40(1): 168-171, 1975

Somatostatin plasma levels and biological effects following subcutaneous administration of somatostatin in man. Acta Endocrinologica 113(4): 465-470, 1986

Plasma somatostatin in normal subjects and in various diseases: increased levels in somatostatin-producing tumors. Hormone and Metabolic Research 14(2): 71-76, 1982

Effects of intravenous somatostatin and (D-Trp8, D-Cys14)-somatostatin on glucose, triglycerides and cholesterol levels in rat plasma. Medical Science Research 20(8): 297-298, 1992

Trh decreases the plasma levels of somatostatin in rabbits with a secondary increase in the plasma levels of glucagon insulin and glucose. Acta Endocrinologica Supplementum 97(243), 1981

The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. Journal of Clinical Endocrinology and Metabolism 64(1): 37-42, 1987

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly. Clujul Medical 88(3): 310-313, 2015